|
US6613804B2
(en)
|
1993-05-20 |
2003-09-02 |
Encysive Pharmaceuticals, Inc. |
Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
|
|
US6500948B1
(en)
|
1995-12-08 |
2002-12-31 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors-compositions, uses preparation and intermediates thereof
|
|
NZ325559A
(en)
*
|
1995-12-08 |
2000-01-28 |
Agouron Pharmaceuticals Inc Ag |
Metalloproteinase inhibitors, pharmaceutical compoMetalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical usitions containing them and their pharmaceutical uses, and methods and intermediates useful for theises, and methods and intermediates useful for their preparation r preparation
|
|
US6747027B1
(en)
*
|
1996-07-22 |
2004-06-08 |
Pharmacia Corporation |
Thiol sulfonamide metalloprotease inhibitors
|
|
US6624177B1
(en)
|
1996-09-04 |
2003-09-23 |
Warner-Lambert Company |
Matrix metalloproteinase inhibitors and their therapeutic uses
|
|
EP0929542A1
(en)
|
1996-09-04 |
1999-07-21 |
Warner-Lambert Company |
Compounds for and a method of inhibiting matrix metalloproteinases
|
|
AU735013B2
(en)
*
|
1996-09-04 |
2001-06-28 |
Warner-Lambert Company |
Matrix metalloproteinase inhibitors and their therapeutic uses
|
|
US5929097A
(en)
*
|
1996-10-16 |
1999-07-27 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
|
US5977408A
(en)
*
|
1996-10-16 |
1999-11-02 |
American Cyanamid Company |
Preparation and use of β-sulfonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US6228869B1
(en)
|
1996-10-16 |
2001-05-08 |
American Cyanamid Company |
Ortho-sulfonamido bicyclic hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US5962481A
(en)
*
|
1996-10-16 |
1999-10-05 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
|
|
US6548524B2
(en)
|
1996-10-16 |
2003-04-15 |
American Cyanamid Company |
Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
|
|
US6174915B1
(en)
|
1997-03-25 |
2001-01-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
|
US6008243A
(en)
*
|
1996-10-24 |
1999-12-28 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them, and their use
|
|
WO1998025597A2
(en)
*
|
1996-12-09 |
1998-06-18 |
Warner-Lambert Company |
Method for treating and preventing heart failure and ventricular dilatation
|
|
EP1366765A1
(en)
*
|
1996-12-17 |
2003-12-03 |
Warner-Lambert Company Llc |
Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing
|
|
DK0946166T3
(da)
|
1996-12-17 |
2004-05-03 |
Warner Lambert Co |
Anvendelse af matrixmetalloproteinaseinhibitorer til fremme af sårheling
|
|
US5985900A
(en)
*
|
1997-04-01 |
1999-11-16 |
Agouron Pharmaceuticals, Inc. |
Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
|
|
HU227183B1
(en)
|
1997-04-28 |
2010-09-28 |
Encysive Pharmaceuticals Inc |
Sulfonamide derivatives and pharmaceutical compositions containing them for the treatment of endothelin-mediated disorders
|
|
DE19719621A1
(de)
|
1997-05-09 |
1998-11-12 |
Hoechst Ag |
Sulfonylaminocarbonsäuren
|
|
ES2165640T3
(es)
|
1997-05-09 |
2002-03-16 |
Hoechst Ag |
Acidos diaminocarboxilicos sustituidos.
|
|
US6410580B1
(en)
|
1998-02-04 |
2002-06-25 |
Novartis Ag |
Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
|
|
EP1918278A1
(en)
|
1998-02-04 |
2008-05-07 |
Novartis AG |
Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
|
|
WO2000015213A1
(en)
*
|
1998-09-11 |
2000-03-23 |
Shionogi & Co., Ltd. |
Remedal or preventive agent for congestive heart failure
|
|
US6858598B1
(en)
|
1998-12-23 |
2005-02-22 |
G. D. Searle & Co. |
Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
|
|
US6313123B1
(en)
|
1999-01-27 |
2001-11-06 |
American Cyanamid Company |
Acetylenic sulfonamide thiol tace inhibitors
|
|
US6762178B2
(en)
|
1999-01-27 |
2004-07-13 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6225311B1
(en)
|
1999-01-27 |
2001-05-01 |
American Cyanamid Company |
Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
|
|
US6946473B2
(en)
|
1999-01-27 |
2005-09-20 |
Wyeth Holdings Corporation |
Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
|
|
US6340691B1
(en)
|
1999-01-27 |
2002-01-22 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
|
|
US6200996B1
(en)
|
1999-01-27 |
2001-03-13 |
American Cyanamid Company |
Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
|
|
US6753337B2
(en)
|
1999-01-27 |
2004-06-22 |
Wyeth Holdings Corporation |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
|
US6277885B1
(en)
|
1999-01-27 |
2001-08-21 |
American Cyanamid Company |
Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6358980B1
(en)
|
1999-01-27 |
2002-03-19 |
American Cyanamid Company |
Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
|
|
US6326516B1
(en)
|
1999-01-27 |
2001-12-04 |
American Cyanamid Company |
Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
|
|
US6465508B1
(en)
|
2000-02-25 |
2002-10-15 |
Wyeth |
Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors
|
|
US20030105144A1
(en)
|
2001-04-17 |
2003-06-05 |
Ping Gao |
Stabilized oral pharmaceutical composition
|
|
BR0213736A
(pt)
|
2001-11-01 |
2004-10-19 |
Wyeth Corp |
ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace
|
|
WO2003053912A1
(en)
*
|
2001-12-20 |
2003-07-03 |
Bristol-Myers Squibb Company |
α-(N-SULPHONAMIDO)ACETAMIDE DERIVATIVES AS β-AMYLOID INHIBITORS
|
|
US6864478B2
(en)
*
|
2002-04-22 |
2005-03-08 |
Visx, Incorporation |
Beam position monitoring for laser eye surgery
|
|
US7199155B2
(en)
|
2002-12-23 |
2007-04-03 |
Wyeth Holdings Corporation |
Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
|
|
CA2511521C
(en)
|
2002-12-30 |
2012-02-07 |
Angiotech International Ag |
Drug delivery from rapid gelling polymer composition
|
|
US7537774B2
(en)
*
|
2005-12-23 |
2009-05-26 |
Orion Therapeautics, Llc |
Therapeutic formulation
|
|
JPWO2007102392A1
(ja)
*
|
2006-03-03 |
2009-07-23 |
塩野義製薬株式会社 |
Ｍｍｐ−１３選択的阻害剤
|
|
US20100099676A1
(en)
*
|
2006-11-02 |
2010-04-22 |
Shionogi & Co., Ltd. |
Sulfonylurea derivative capable of selectively inhibiting mmp-13
|
|
US8084477B2
(en)
|
2007-10-31 |
2011-12-27 |
Bristol-Myers Squibb Company |
Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
|
|
US8093276B2
(en)
*
|
2007-10-31 |
2012-01-10 |
Bristol-Myers Squibb Company |
Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
|
|
JP2011523633A
(ja)
*
|
2008-05-08 |
2011-08-18 |
ブリストル−マイヤーズ スクイブ カンパニー |
２−アリールグリシンアミド誘導体
|
|
US8044077B2
(en)
*
|
2009-03-19 |
2011-10-25 |
Bristol-Myers Squibb Company |
Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
|
|
US20110071199A1
(en)
*
|
2009-03-20 |
2011-03-24 |
Bristol-Myers Squibb Company |
Thiophenyl Sulfonamides for the Treatment of Alzheimer's Disease
|
|
US7977362B2
(en)
*
|
2009-03-20 |
2011-07-12 |
Bristol-Myers Squibb Company |
Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
|
|
US8252821B2
(en)
*
|
2009-04-14 |
2012-08-28 |
Bristol-Myers Squibb Company |
Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
|
|
TW201043269A
(en)
*
|
2009-04-14 |
2010-12-16 |
Bristol Myers Squibb Co |
Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
|